NANJING, China, Jan. 13, 2011 /PRNewswire-Asia/ — Simcere
Pharmaceutical Group (“Simcere” or the “Company”) (NYSE:
SCR), a leading pharmaceutical company specializing in the
development, manufacturing, and marketing of branded and
proprietary pharmaceuticals in China, today announced the
resignation of chief financial officer Mr. Frank Zhao for personal
reasons, effective January 15, 2011. Simcere’s Board of Directors
has appointed Mr. Yushan Wan, Simcere’s corporate controller, as
acting chief financial officer as of the effective date.
“Frank has been a valuable member of our management team and we
wish him all the best in his future endeavors,” said Mr. Jinsheng
Ren, chairman and chief executive officer of Simcere. “I would like
to thank him for making great enhancements to our financial
management and internal control systems in the past four years, as
well as building strong relationships with the investment
community.”
Mr. Yushan Wan joined Simcere in 2000 and has been serving as
the Company’s corporate controller since 2007. Mr. Wan has a
bachelor’s degree in biochemistry and a master’s degree in
accounting from Nanjing University and is a Chinese Certified
Public Accountant.
Mr. Ren commented, “Yushan has a decade of experience working in
Simcere’s financial department and was most recently our corporate
controller. I am confident that with his support we will have a
smooth transition ahead of the appointment of a new CFO.”
About Simcere Pharmaceutical GroupSimcere Pharmaceutical
Group (NYSE: SCR, Simcere) is a leading pharmaceutical company
specializing in the development, manufacturing, and marketing of
branded generic and proprietary pharmaceuticals in China. In recent
years, Simcere has been focusing its strategy on the development of
innovative pharmaceuticals and first-to-market generics. The
Company has introduced an innovative anti-ca
‘/>”/>
